Drug Approval | July 23, 2024
Renews GMP certifications for India and Malaysia sites
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
Both organisations enter into a long- term collaboration to expand patient access in India
The drug will target specific genetic mutations prevalent in certain types of cancers
Subscribe To Our Newsletter & Stay Updated
